![](https://endpts.com/wp-content/uploads/2021/02/epn_weekly_tile.jpg)
Gilead's $4.3B liver bet; WuXi under fire; Exscientia CEO’s ouster; Late Friday cell therapy approval; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.